Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Severely Obese Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Body mass index (BMI) greater than or equal to (\>=) 35 to less than or equal to (\<=) 50 kilogram per square meter (kg/m\^2) at the screening visit~* Stable weight (that is, change of \<= 5 percent \[%\] within 12 weeks before screening based on medical history)~* Women must be either: (a) Postmenopausal, or (b) Permanently sterilized or otherwise be incapable of pregnancy, or (c) Heterosexually active and practicing a highly effective method of birth control, or (d) Not heterosexually active~* Woman of childbearing potential have a negative pregnancy test at screening~* Willing and able to adhere to specific the prohibitions and restrictions~Exclusion Criteria:~* History of obesity with a known secondary cause (for example, Cushing's disease/syndrome)~* History of Type 1 diabetes mellitus, Type 2 diabetes mellitus (T2DM), diabetic ketoacidosis (DKA), pancreas or beta-cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy~* Has a Hemoglobin A1c (HbA1c) of \>= 6.5% or fasting plasma glucose (FPG) \>= 126 milligrams per deciliter (mg/dL) (\>= 7.0 millimoles per liter \[mmol/L\]) at screening~* Screening calcitonin of \>= 50 picograms per milliliter (pg/mL) personal history or family history of medullary thyroid cancer, or of multiple endocrine neoplasia syndrome type 2 (MEN 2), regardless of time prior to screening~* History of glucagonoma

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Double-Blind: JNJ-64565111 Dose Level 1 (Type: EXPERIMENTAL): Participants will receive a JNJ-64565111 Dose Level 1 subcutaneously (SC) once-weekly for 26-week treatment phase.
- Double-Blind: JNJ-64565111 Dose Level 2 (Type: EXPERIMENTAL): Participants will receive a JNJ-64565111 Dose Level 2 SC once-weekly for 26-week treatment phase.
- Double-Blind: JNJ-64565111 Dose Level 3 (Type: EXPERIMENTAL): Participants will receive a JNJ-64565111 Dose Level 3 SC once-weekly for 26-week treatment phase.
- Double-Blind: Placebo (Type: PLACEBO_COMPARATOR): Participants will receive placebo matching to JNJ-64565111 SC once-weekly for 26-week treatment phase.
- Open-Label: 3.0 milligram (mg) Liraglutide (Type: ACTIVE_COMPARATOR): Participant will receive once-daily doses of 0.6, 1.2, 1.8, 2.4, or 3.0 mg. The participants will receive liraglutide at a starting dose of 0.6 mg SC once-daily on Day 1. Participants will be instructed to increase the dose of liraglutide by 0.6 mg dose increment every 7 days, up to the full dosage of 3.0 mg by Week 5. Participants will then continue on the 3.0 mg once-daily dosage until Week 26.

Based on this trial design, predict the completion outcome and termination type (if applicable).